%0 Journal Article
%T Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
%A Z. Einbeigi
%A D. Bergstr£¿m
%A T. Hatschek
%A M. Malmberg
%J Clinical Medicine : Oncology
%D 2008
%I 
%X Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m2, paclitaxel 155 mg/m2 (both day 1) and capecitabine 665 mg/m2 twice daily (days 1¨C14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
%K epirubicin
%K paclitaxel
%K capecitabine
%K first-line chemotherapy
%K metastatic breast cancer
%K phase I/II
%U http://www.la-press.com/paclitaxel-epirubicin-and-capecitabine-tex-as-first-line-treatment-for-a1051